Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000473311 | SCV000563474 | benign | Neurofibromatosis, type 2 | 2024-02-01 | criteria provided, single submitter | clinical testing | |
Athena Diagnostics Inc | RCV000516813 | SCV000614194 | benign | not specified | 2016-12-30 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV000562252 | SCV000674136 | likely benign | Hereditary cancer-predisposing syndrome | 2017-03-20 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Mendelics | RCV000473311 | SCV000839522 | benign | Neurofibromatosis, type 2 | 2023-08-22 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000516813 | SCV000917899 | benign | not specified | 2018-11-19 | criteria provided, single submitter | clinical testing | Variant summary: NF2 c.1386C>T alters a non-conserved nucleotide resulting in a synonymous change. Several computational tools predict a significant impact on normal splicing: Five predict the variant creates a cryptic 5' donor site. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 0.00034 in 210304 control chromosomes, predominantly at a frequency of 0.0033 within the African subpopulation in the gnomAD database. The observed variant frequency within African control individuals in the gnomAD database is approximately 174 fold of the estimated maximal expected allele frequency for a pathogenic variant in NF2 causing Neurofibromatosis Type 2 phenotype (1.9e-05), strongly suggesting that the variant is a benign polymorphism found primarily in populations of African origin. To our knowledge, no occurrence of c.1386C>T in individuals affected with Neurofibromatosis Type 2 and no experimental evidence demonstrating its impact on protein function have been reported. Four clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation, 3 classified as likely benign/benign while one classified as VUS. Based on the evidence outlined above, the variant was classified as benign. |
Genome- |
RCV000473311 | SCV002045409 | benign | Neurofibromatosis, type 2 | 2021-11-07 | criteria provided, single submitter | clinical testing | |
Sema4, |
RCV000562252 | SCV002528177 | likely benign | Hereditary cancer-predisposing syndrome | 2021-08-23 | criteria provided, single submitter | curation | |
KCCC/NGS Laboratory, |
RCV000473311 | SCV004016460 | benign | Neurofibromatosis, type 2 | 2023-07-07 | criteria provided, single submitter | clinical testing |